Discover how Revology Analytics propels mid-market businesses to sustainable, profitable growth by building advanced, in-house Revenue Growth Analytics & Management (RGM) capabilities—fast.
Our senior expert-led, hands-on approach ensures you own the tools, insights, strategy and processes needed to thrive long-term.
We would love to hear from you.
Let’s chat!
Gain exclusive access to the latest insights from over 150 commercial leaders on the state of Revenue Growth Analytics in 2025, based on our expanded Revenue Growth Analytics Maturity Scorecard™.
Discover how Revology Analytics propels mid-market businesses to sustainable, profitable growth by building advanced, in-house Revenue Growth Analytics & Management (RGM) capabilities—fast.
Our senior expert-led, hands-on approach ensures you own the tools, insights, strategy and processes needed to thrive long-term.
We would love to hear from you.
Let’s chat!
Gain exclusive access to the latest insights from over 150 commercial leaders on the state of Revenue Growth Analytics in 2025, based on our expanded Revenue Growth Analytics Maturity Scorecard™.
Pharmaceutical pricing language must stay precise. Revology co-designs governed AI pricing analytics, contract economics, and tier governance systems, with legal review before publication.
Pharmaceutical pricing pages need precision, and pharma pricing itself needs structure that survives scrutiny. Revology co-designs the analytics and builds the capability inside pharmaceutical commercial teams: an automated Product Equivalence Matrix that maps each product to true competitor equivalents (one recent build reached 95%-plus SKU coverage), causal elasticity models using Double Machine Learning that separate real price sensitivity from promotions, supply swings, and competitor moves, a Competitive Price Index that flags under- and over-priced SKUs, and scenario simulators that project volume, revenue, and gross-profit impact before a price moves — surfacing the Pricing Quick Wins worth acting on first. The work integrates internal sales and cost data with syndicated sources and normalizes to standard units. It is scoped to pricing and revenue decisions, not clinical efficacy or patient outcomes. For mid-market and business-unit teams ($100M–$2B), keep regulated-industry counsel review on final copy wherever reimbursement, access, or outcomes language appears.
Pharmaceutical companies contend with intense branded generic competition, overlapping regulations, and high-stakes pricing decisions. Relying on static spreadsheets or simple benchmarks is no longer enough. Our pharma work focuses on three pillars:
Beyond analytics, we emphasize capability building—training your teams to maintain the PEM, refresh models, interpret outputs, and embed pricing analytics into standard business rhythms so value continues to compound after the project ends.
Rules-based equivalence logic achieving >95% SKU coverage and harmonizing internal product views with IQVIA market data.
Causal ML-based price elasticity models and a recommendation engine that surfaced SKU-level price opportunities with quantified volume, revenue, and margin tradeoffs.
Training, documentation, and governance frameworks that embedded PEM maintenance, model refresh cycles, and pricing decision standards into day-to-day operations.
Excel/BI tools that allowed local teams to simulate price moves, evaluate CPI positions, and communicate impact in a common language to finance and leadership.
Have a Revenue Growth Analytics pain point, a question, or a content suggestion?
The Hurt Hub@Davidson
210 Delburg St, Davidson, NC 28036, United States
+1 803-701-9243
We would love to hear from you.
This guide outlines six methods for estimating willingness to pay and the governance needed to translate these estimates into effective pricing decisions. Many companies set
Some companies are already using AI well. But most mid-market Manufacturers and Distributors are not. A lot of what’s out there is either theory or built for teams with data scientists and a big software budget, so plenty of commercial teams are stuck, knowing they should do more with AI but not knowing where to start.
How data brokers and identity graphs quietly set personalized prices: what the evidence proves, what it doesn’t, and how pricing leaders should govern the risk.
A Pricing & RGM Analytics Navigator Your Team Owns — Six Modules, One GL-Reconciled Foundation, and the Agent Layer That Follows Most CPG Pricing and
A pharma pricing analytics engine is a governed decision-support system that integrates transaction, contract, channel, market, macroeconomic, regulatory, and competitive data to improve price setting,
This manual is designed for CEOs, CFOs, CCOs, Pricing and RGM leaders, and commercial analytics teams at mid-market CPG manufacturers. It outlines six decision modules,
Revology Analytics® is the end-to-end Pricing & Revenue Growth Management advisory firm for mid-market companies: strategy and governance, AI-enabled analytics, and the adoption that turns both into profit.
Over 225 companies took our scorecard to improve their Revenue Growth Analytics & Management capabilities.
Copyright © 2026 Revology Analytics LLC
